Form 8-K - Current report:
SEC Accession No. 0001193125-24-196513
Filing Date
2024-08-08
Accepted
2024-08-08 08:25:01
Documents
16
Period of Report
2024-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d879446d8k.htm   iXBRL 8-K 25791
2 EX-99.1 d879446dex991.htm EX-99.1 70002
6 GRAPHIC g879446g0803101051372.jpg GRAPHIC 2767
7 GRAPHIC g879446g0805155158890.jpg GRAPHIC 2222
  Complete submission text file 0001193125-24-196513.txt   240159

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20240808.xsd EX-101.SCH 2889
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20240808_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20240808_pre.xml EX-101.PRE 11287
19 EXTRACTED XBRL INSTANCE DOCUMENT d879446d8k_htm.xml XML 3670
Mailing Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453
Business Address 221 CRESCENT STREET SUITE 103A WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

EIN.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 241186213
SIC: 8071 Services-Medical Laboratories
(CF Office: 08 Industrial Applications and Services)